Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nancy Kuntz

Neurology with Special Qualifications in Child Neurology Chicago, IL Medical Doctor

NPI 1114999125 CMS profile 537417

225 E Chicago Ave # 51, Chicago, IL 60611

Open in the dashboard

General payments

$502,602

335 records reported · program years 2019–2025

Research payments

$8,419

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,074,789 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Nancy Kuntz of Chicago, IL is reported in the CMS Open Payments database as having received $502,602 across 335 general payments and $8,419 in research payments paid to them. Separately, studies naming them as principal investigator received $7,074,789 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $139,584 52
2025 Research $1,400 1
2024 General $134,131 72
2024 Research $1,400 1
2023 General $111,691 58
2023 Research $4,219 6
2022 General $50,885 41
2022 Research $1,400 1
2021 General $20,281 13
2020 General $20,813 27
2019 General $25,217 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Kuntz
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Nancy Kuntz were reported at $139,584. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Nancy Kuntz Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $25,217 $262 $68–$1,313 $163
2020 $20,813 $188 $46–$1,222 $114
2021 $20,281 $183 $45–$1,356 $132
2022 $50,885 $229 $72–$1,177 $149
2023 $111,691 $269 $93–$1,195 $160
2024 $134,131 $300 $98–$1,428 $164
2025 $139,584 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $370,370 136 payments
  2. Genentech USA, Inc. $37,852 28 payments
  3. AveXis $29,936 87 payments
  4. Argenx US, Inc. $18,954 24 payments
  5. F. Hoffmann-La Roche AG $18,531 5 payments
  6. Biogen, Inc. $13,385 24 payments
  7. Catalyst Pharmaceuticals, Inc. $7,902 10 payments
  8. Janssen Scientific Affairs, LLC $2,244 4 payments
  9. ITF Therapeutics LLC $1,767 3 payments
  10. Pfizer Inc. $1,137 4 payments
  11. Other $524 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $403,345 90 payments
  2. Travel and Lodging $34,716 54 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,152 16 payments
  4. Education $17,702 66 payments
  5. Honoraria $14,998 6 payments
  6. Food and Beverage $7,690 103 payments
Products named General payments · program years 2019–2025
  1. ZOLGENSMA Gene Therapy $29,741 83 payments
  2. Evrysdi $24,948 24 payments
  3. VYVGART Hytrulo $9,132 12 payments
  4. Non-Covered Product $6,934 6 payments
  5. SPINRAZA $6,415 17 payments
  6. AGAMREE $5,502 9 payments
  7. Exondys 51 $3,300 1 payment
  8. VYVGART $1,676 3 payments
  9. ZOLGENSMA Neurology $251 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sarepta Therapeutics, Inc. $6,185 8 payments
  2. F. Hoffmann-La Roche AG $2,233 1 payment

Records

344 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record